Amgen Inc. (AMGN) FY2024 Annual P&L / Income Statement
2024-01-01 to 2024-12-31
Revenue by Product and Service by Geography
2024-01-01 to 2024-12-31
Swipe to see the full flow
Chart details
Amgen Inc. (AMGN) FY2024 Annual P&L / Income Statement
Income statement for 2024-01-01 through 2024-12-31. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.
- Total revenues
- 33,424,000,000 US dollars
- Cost of sales
- 12,858,000,000 US dollars
- Gross profit (calculated)
- 20,566,000,000 US dollars
- Operating expenses (calculated)
- 13,308,000,000 US dollars
- Operating income
- 7,258,000,000 US dollars
- Other income (expense), net (calculated)
- negative 2,649,000,000 US dollars
- Income before income taxes
- 4,609,000,000 US dollars
- Provision for income taxes
- 519,000,000 US dollars
- Net income
- 4,090,000,000 US dollars
- Aranesp - UNITED STATES
- 386,000,000 US dollars
- Aranesp - Non-US
- 956,000,000 US dollars
- BLINCYTO - UNITED STATES
- 800,000,000 US dollars
- BLINCYTO - Non-US
- 416,000,000 US dollars
- EVENITY - UNITED STATES
- 1,131,000,000 US dollars
- EVENITY - Non-US
- 432,000,000 US dollars
- ENBREL - UNITED STATES
- 3,288,000,000 US dollars
- ENBREL - Non-US
- 28,000,000 US dollars
- KRYSTEXXA - UNITED STATES
- 1,185,000,000 US dollars
- KRYSTEXXA - Non-US
- 0 US dollars
- Kyprolis - UNITED STATES
- 948,000,000 US dollars
- Kyprolis - Non-US
- 555,000,000 US dollars
- Nplate - UNITED STATES
- 970,000,000 US dollars
- Nplate - Non-US
- 486,000,000 US dollars
- Otezla - UNITED STATES
- 1,699,000,000 US dollars
- Otezla - Non-US
- 427,000,000 US dollars
- Other products - UNITED STATES
- 4,037,000,000 US dollars
- Other products - Non-US
- 1,593,000,000 US dollars
- Prolia - UNITED STATES
- 2,885,000,000 US dollars
- Prolia - Non-US
- 1,489,000,000 US dollars
- Repatha - UNITED STATES
- 1,139,000,000 US dollars
- Repatha - Non-US
- 1,083,000,000 US dollars
- TEPEZZA - UNITED STATES
- 1,835,000,000 US dollars
- TEPEZZA - Non-US
- 16,000,000 US dollars
- TEZSPIRE - UNITED STATES
- 972,000,000 US dollars
- TEZSPIRE - Non-US
- 0 US dollars
- Vectibix - UNITED STATES
- 519,000,000 US dollars
- Vectibix - Non-US
- 526,000,000 US dollars
- XGEVA - UNITED STATES
- 1,507,000,000 US dollars
- XGEVA - Non-US
- 718,000,000 US dollars
- Other revenues - UNITED STATES
- 562,000,000 US dollars
- Other revenues - Non-US
- 836,000,000 US dollars
- Product sales - UNITED STATES
- 23,301,000,000 US dollars
- Product sales - Non-US
- 8,725,000,000 US dollars
- Research and development
- 5,964,000,000 US dollars
- Selling, general and administrative
- 7,096,000,000 US dollars
- Other
- 248,000,000 US dollars
- Revenue before reconciliation (calculated)
- 65,450,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.
- Components above reported revenue (calculated)
- negative 32,026,000,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item.
Chart connections
- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG
Gross margin
61.5%
Gross profit / revenue
Operating margin
21.7%
Operating profit / revenue
Cash conversion
280.9%
Operating cash / net income, same period
Product waitlist
Health Check and Teardown for your own company
A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!